ES2194933T3 - Inhibidores de la agregacion plaquetaria. - Google Patents

Inhibidores de la agregacion plaquetaria.

Info

Publication number
ES2194933T3
ES2194933T3 ES95944838T ES95944838T ES2194933T3 ES 2194933 T3 ES2194933 T3 ES 2194933T3 ES 95944838 T ES95944838 T ES 95944838T ES 95944838 T ES95944838 T ES 95944838T ES 2194933 T3 ES2194933 T3 ES 2194933T3
Authority
ES
Spain
Prior art keywords
inhibitors
aggregation
compounds
plaquetary
plaquetary aggregation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95944838T
Other languages
English (en)
Inventor
Peter Gerrard Ruminski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of ES2194933T3 publication Critical patent/ES2194933T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS QUE TIENEN LA FORMULA (I) O A UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS QUE SON UTILES EN LA INHIBICION DE LA AGREGACION PLAQUETARIA, A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN EL COMPUESTO Y A UN METODO PARA INHIBIR LA AGREGACION PLAQUETARIA EN MAMIFEROS MEDIANTE AL ADMINISTRACION DE TALES COMPUESTOS Y COMPOSICIONES.
ES95944838T 1995-01-17 1995-12-15 Inhibidores de la agregacion plaquetaria. Expired - Lifetime ES2194933T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/375,338 US5602155A (en) 1995-01-17 1995-01-17 Platelet aggregation inhibitors

Publications (1)

Publication Number Publication Date
ES2194933T3 true ES2194933T3 (es) 2003-12-01

Family

ID=23480498

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95944838T Expired - Lifetime ES2194933T3 (es) 1995-01-17 1995-12-15 Inhibidores de la agregacion plaquetaria.

Country Status (11)

Country Link
US (2) US5602155A (es)
EP (1) EP0804418B1 (es)
JP (1) JPH10512581A (es)
AT (1) ATE235468T1 (es)
AU (1) AU5710696A (es)
CA (1) CA2210746A1 (es)
DE (1) DE69530123T2 (es)
DK (1) DK0804418T3 (es)
ES (1) ES2194933T3 (es)
PT (1) PT804418E (es)
WO (1) WO1996023771A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602155A (en) * 1995-01-17 1997-02-11 G. D. Searle & Co. Platelet aggregation inhibitors
US6087332A (en) * 1997-12-23 2000-07-11 Galler; Lawrence Isaac Streptokinase derivatives with high affinity for activated platelets and methods of their production and use in thrombolytic therapy
US6117842A (en) * 1998-03-09 2000-09-12 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2352957A1 (en) * 1999-09-29 2001-04-05 Ortho-Mcneil Pharmaceutical, Inc. Isonipecotamides for the treatment of integrin-mediated disorders
US20040058915A1 (en) * 2000-08-29 2004-03-25 Khanna Ish Kumar Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
US20020072500A1 (en) * 2000-09-27 2002-06-13 Thomas Rogers Hydroxy acid integrin antagonists
US6720327B2 (en) * 2000-09-27 2004-04-13 Pharmacia Corporation Lactone integrin antagonists
EP1389205B1 (en) * 2001-04-09 2005-12-21 Ortho-McNeil Pharmaceutical Research Inc. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
US20040019206A1 (en) * 2001-09-27 2004-01-29 Peter Ruminiski Lactone integrin antagonists
WO2003050261A2 (en) 2001-12-10 2003-06-19 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
AU2003299600A1 (en) * 2002-12-20 2004-07-29 Pharmacia Corpration The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
IN2015DN00099A (es) 2012-07-18 2015-05-29 Univ Saint Louis
RU2729518C2 (ru) 2015-12-30 2020-08-07 Сент-Луис Юниверсити Мета-азациклические производные аминобензойной кислоты в качестве антагонистов пан-интегрина

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857508A (en) * 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
US4879313A (en) * 1988-07-20 1989-11-07 Mosanto Company Novel platelet-aggregation inhibitors
CA2066047A1 (en) * 1989-09-29 1991-03-30 Scott I. Klein Anti-thrombotic peptides and pseudopeptides
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
NZ239876A (en) * 1990-09-27 1993-12-23 Merck & Co Inc Glycyl-b-alanine derivatives and pharmaceutical compositions thereof.
JPH06505978A (ja) * 1991-02-05 1994-07-07 スミスクライン・ビーチャム・コーポレイション 芳香族エステルまたはアミドを含有する抗凝集性ペプチド
MX9201416A (es) * 1991-03-28 1992-10-01 Rhone Poulenc Rorer Int Peptidos y pseudopeptidos antitromboticos.
US5321034A (en) * 1991-05-07 1994-06-14 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2117282A1 (en) * 1991-11-22 1993-05-27 Ofer Lider Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprosing them
WO1994021602A1 (en) * 1993-03-15 1994-09-29 G.D. Searle & Co. Urea derivatives useful as platelet aggregation inhibitors
US5602155A (en) * 1995-01-17 1997-02-11 G. D. Searle & Co. Platelet aggregation inhibitors

Also Published As

Publication number Publication date
EP0804418B1 (en) 2003-03-26
ATE235468T1 (de) 2003-04-15
DE69530123T2 (de) 2004-02-05
CA2210746A1 (en) 1996-08-08
WO1996023771A2 (en) 1996-08-08
US5798370A (en) 1998-08-25
DE69530123D1 (en) 2003-04-30
DK0804418T3 (da) 2003-07-07
JPH10512581A (ja) 1998-12-02
AU5710696A (en) 1996-08-21
PT804418E (pt) 2003-08-29
EP0804418A2 (en) 1997-11-05
US5602155A (en) 1997-02-11
WO1996023771A3 (en) 1996-10-10

Similar Documents

Publication Publication Date Title
NO953844L (no) 1-amidinofenyl-pyrrolidoner piperidinoner azetinoner som plateaggregeringshemmere
ES2194933T3 (es) Inhibidores de la agregacion plaquetaria.
DK0715623T3 (da) Blodpladeaggregationsinhibitorer
CO5600999A2 (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
CO5680428A2 (es) Antagonistas del receptor de trombina
AR018732A1 (es) Iminoazucares alquilados para prevenir, reducir o revertir la resistencia a la multidroga en el tratamiento quimioterapeutico y composicionfarmaceutica que los contiene.
AR033688A1 (es) Composicion parenteral reconstituible
CO5261556A1 (es) Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
CR6106A (es) Desnaturalizantes para sales aminas simpaticomimeticas
CO5070569A1 (es) Compuesto de aminoazol o una sal farmaceuticamente aceptable del mismo y medicamento que los contienen
PA8616201A1 (es) Composiciones farmaceuticas de liberacion sostenida
CO5280073A1 (es) Composiciones
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
DK0659193T3 (da) Blodpladeaggregationsinhibitorer
CL2004000765A1 (es) Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo.
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
AR023344A1 (es) 4-ariloxiindoles, una composicion farmaceutica que los contienen y el uso de los mismos para la preparacion de medicamentos
KR960700053A (ko) 방사선회복제로서 리루졸의 이용(application of riluzole as a radiorestorer)
AR029339A1 (es) Derivados del tetrahidropirano, un proceso para su preparacion, una composicion farmaceutica que los comprende y el uso de dichos derivados para la elaboracion de un medicamento
GT199900123A (es) Un metodo para la prevencion del inicio del asma.
KR950005312A (ko) 간질환 치료 및 간기능 개선용 의약조성물